Sublingual esketamine for PTSD. The same inflammatory pathways that drive PTSD also appear in autoimmune disease — an exploratory neuroimmune signal we are measuring in the trial.
*Sertraline (1999) and paroxetine (2001) are the only FDA-approved PTSD medications. Both are 1990s SSRIs. No novel mechanism has been approved in over 25 years. Sources: FDA, SAMHSA, Precedence Research (PTSD therapeutics market, $3.55B by 2035).
Emerging evidence shows that PTSD is associated with chronically elevated levels of pro-inflammatory cytokines — including IL-6, IL-1β, TNF-α, and CRP — that persist long after the traumatic event. These biomarkers disrupt hippocampal neurogenesis, impair BDNF signaling, and perpetuate the hyperarousal and avoidance symptoms that define the disorder.
Existing pharmacotherapies — SSRIs, SNRIs, prazosin — address neurotransmitter balance but leave the inflammatory substrate largely untreated. This is a core reason why 40–60% of PTSD patients fail to achieve remission.
3.6 million treatment-resistant PTSD patients have already exhausted every approved option. Only 2 FDA-approved drugs exist for the primary indication — both over 20 years old — and neither addresses the neurobiological substrate. The FDA has rejected both recent approval attempts: MDMA-assisted therapy (2024) and brexpiprazole+sertraline (2025, after a 1–10 advisory committee vote). These same inflammatory markers (IL-6, TNF-α, IL-17, interferon α/β) are central to autoimmune biology — a convergence we think is worth measuring as an exploratory signal in the trial, not a second indication.
Passos et al. (2015). "Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression." JAMA Psychiatry, 72(2), 192–200. Meta-analysis of 20 studies, N>1,000.
Spravato (esketamine nasal spray) received FDA approval in 2019 for treatment-resistant depression — not PTSD. While its mechanism is highly relevant, its in-clinic model and cost — roughly $14,000–24,000 in the first year once drug and per-dose clinic administration are combined — create a prohibitive access barrier. Meanwhile, unregulated compounded troches ($100–150/month, no oversight, dissociative doses) fill the vacuum with no FDA path, no insurance pathway, and no standardized safety monitoring.
The gap between Spravato and unregulated troches is where Project Lucid lives: FDA-regulated, low-dose, at-home, and designed from the ground up for PTSD.
These same PTSD patients carry roughly twice the rate of autoimmune disease (O’Donovan et al., 2015; N=666,269; adjusted RR 2.00 vs. no psychiatric diagnosis). A 2025 meta-analysis of 1.98M patients (Mandagere et al.) independently confirms the association across study designs, with a pooled RR of 1.29. The mechanism that rewires trauma also modulates the immune pathways targeted by Skyrizi, Cosentyx, and Humira — a mechanistic convergence worth investigating in the trial biomarker panel.
The regulatory bar was set in 2024, when the FDA rejected MDMA-assisted therapy for PTSD — the most high-profile novel approach in years. The agency’s now-published Complete Response Letter cited unreported adverse events undermining the safety data, unestablished durability, and bias/functional-unblinding concerns, and demanded a new trial plus an independent audit. Since then the field has validated the market rather than closed it: Otsuka acquired the Phase 2 methylone program for up to $1.2B and the MDMA application was resubmitted in August 2026 — and every advancing candidate remains a clinic-administered, monitored-session model. Ketamine’s placebo-controlled RCT record, delivered as a take-home film, is the evidence shape the agency demanded in the delivery model none of them offer.
The 50mg sublingual esketamine film (manufactured by LTS Lohmann) operates through two complementary mechanisms simultaneously — rapid neuroplasticity induction and direct anti-inflammatory action. Project Lucid’s clinical program is the first to test this film for PTSD with an integrated exploratory neuroimmune biomarker panel.
Durability comes from frequency — not dose. And the same mechanism that rewires trauma modulates IL-17, TNF-α, and interferon signaling — the targets of Skyrizi, Humira, and Cosentyx.
NMDA receptor antagonism triggers downstream BDNF release, promoting synaptogenesis in the prefrontal cortex and hippocampus within hours — not weeks.
Esketamine directly suppresses pro-inflammatory cytokines IL-6 and TNF-α — addressing the neuroinflammatory substrate that conventional PTSD treatments leave untreated.
Sublingual film achieves ~29% bioavailability with rapid Tmax (~19 min) — parent-drug Cmax comparable to Spravato 56–84mg intranasal — without requiring in-clinic administration after the first supervised dose.
| Dimension | Project Lucid | Spravato (J&J) | IV Ketamine Clinics | Compounded Troches |
|---|---|---|---|---|
| Delivery | Sublingual film | Nasal spray | Intravenous infusion | Sublingual troche (lozenge) |
| Active Ingredient | Esketamine (50mg) | Esketamine (56–84mg) | Racemic ketamine | Racemic ketamine (compounded) |
| Setting | At-home after first clinic dose | In-clinic only (2-hr monitoring) | In-clinic only (45–60 min infusion) | At-home, unsupervised |
| Dosing Frequency | 3×/week | 2×/week → 1×/week maintenance | Varies (1–2×/week) | Variable (prescriber-dependent) |
| PTSD Indication | Primary target | Not indicated (TRD only) | Off-label | Off-label, unregulated |
| Neuroimmune Mechanism | Core thesis: dual-pathway | Not positioned | Not positioned | Not positioned |
| Dose Level | Sub-dissociative | Can be dissociative | Often dissociative | Often dissociative |
| Cost Model | Designed for accessibility | ~$900/session (before insurance) | $400–800/infusion | $100–150/month (cash pay) |
| Reimbursement Target | Insurance-reimbursable target | Limited (specialty pharmacy) | Rarely covered | Not covered (no FDA path) |
The sublingual film is the therapeutic. The digital monitoring platform is what makes at-home administration safe, measurable, and scalable. This is the technology our patent protects.
All 12 dosing sessions per participant administered under direct clinical supervision with 2-hour post-dose monitoring. Vitals, CADSS, and SpO₂ collected at every session. Establishes the dose–response and safety profile.
First doses in clinic, maintenance doses transition to at-home with real-time digital monitoring. The platform tracks vitals, mood, dissociation, and safety checkpoints — flagging alerts to the treating clinician before, during, and after each dose.
FDA-regulated at-home esketamine with continuous digital safety infrastructure. Remote vitals, real-time dissociation scoring, between-dose symptom tracking, telehealth check-ins, and automated safety escalation. Positioned as a psychiatric therapy with a reimbursement target comparable to Spravato.
Patent-pending: Digital Systems for Remote Administration and Monitoring of Sublingual Esketamine for PTSD (Provisional Serial Nos. 63/785,736; 63/799,047; 63/804,512). PCT international application filed April 2026.
Ketamine dosing is nonlinear — too little is sub-therapeutic, too much is dissociative — and the optimum in PTSD has never been established: the largest IV dose-ranging trial was inconclusive, and recent reviews report conflicting dose signals. Spravato’s fixed 56/84mg steps assume an optimum no one has mapped. Project Lucid is designed for dose individualization — 25mg tiles combine to deliver 25, 50, 75, 100, 125, or 150mg per session within a single label. The Phase 1/2a trial anchors that curve directly: a randomized dose-ranging comparison of 50mg and 100mg against placebo.
A differentiated, defensible label at Phase 3 — built on a dose–response question the field has not answered, and that LUCID-PTSD-2026-001 is designed to.
Spravato’s REMS mandates in-clinic observation for every dose. Project Lucid’s platform captures HR, SpO₂, dissociation (CADSS), and symptom data remotely — designed to demonstrate non-inferiority to in-clinic observation and unlock an at-home label. Prior art exists: MindMed (now Definium Therapeutics) took its session-monitoring system through an FDA CDRH pre-submission meeting in 2021 — device-pathway precedent for remote session monitoring. DEA telehealth flexibilities for controlled-substance prescribing were extended through 2026, with a permanent framework in rulemaking.
Project Lucid’s lead study is a randomized, double-blind, placebo-controlled Phase 1/2a dose-ranging trial — N≈84 across three arms (placebo / 50mg / 100mg, 1:1:1) — of sublingual esketamine film 3×/week for 4 weeks in adults with PTSD, adjunctive to stable standard of care. CAPS-5 dose–response is the primary analysis, with a pre-specified neuroimmune biomarker aim (CRP, IL-6, TNF-α, BDNF) and a PK substudy across dose arms. The trial is designed to be funded by a ~$6.25M DoD PRMRP Clinical Trial Award (application in progress), pairing non-dilutive trial funding with seed equity. Each milestone below represents an investor catalyst event.
Pre-application submitted to the FY26 Peer Reviewed Medical Research Program Clinical Trial Award (~$6.25M program: 12-month planning phase + 4-year trial); full application September 2026. Protocol LUCID-PTSD-2026-001 (v4.2) complete: randomized, double-blind, double-dummy, placebo-controlled dose-ranging design with independent 3-member DSMB. Written-response Pre-IND submission to FDA in preparation.
Active$3.25M SAFE closes. Seed capital funds the company — Pre-IND and IND package, patent national-phase filings, placebo film development with LTS Lohmann, site contracting, and operations — while the DoD award, if granted, funds the trial itself. Each seed dollar controls roughly 3× its value in program spend.
Written-response Pre-IND with FDA to align on the 505(b)(2) reference products, PK bridging, and CMC requirements. PRMRP award notification and anticipated award start in late 2027. Clinical site subaward executed with a leading academic medical center PTSD/depression research program.
12-month DoD-funded planning phase: 505(b)(2) IND submission (cross-referencing the esketamine and ketamine reference packages) and FDA safe-to-proceed, GMP drug and matched placebo supply from LTS Lohmann, site activation, IRB and DoD HRPO approvals. IND clearance is itself a valuation catalyst.
Randomized dose-ranging trial: N≈84 adults with PTSD, placebo / 50mg / 100mg (1:1:1), 12 sessions over 4 weeks, CAPS-5 dose–response primary analysis with Week-12 durability, safety co-equal (CADSS, C-SSRS, vitals), PK substudy, and the 4-analyte neuroimmune biomarker aim. A positive readout catalyzes Phase 2b design, out-licensing conversations, and the Series A. If the exploratory neuroimmune signal is confirmed, it informs future mechanistic research partnerships.
All dosing sessions include 2-hour post-dose monitoring with validated dissociation assessment (CADSS) and vital sign tracking. Explicit discharge criteria gate home release. C-SSRS suicidality screening at every visit. Independent 3-member DSMB with pre-specified stopping rules for any serious adverse event. The safety protocol was designed to demonstrate clinical viability — not just regulatory compliance.
The case for Project Lucid is not speculative — it rests on a converging body of clinical, pharmacokinetic, and mechanistic evidence. Repeated IV ketamine 3×/week produced a 67% response rate in the landmark randomized trial (Feder 2021, d=1.13) and 69% with d=1.9 in open-label combination with written exposure therapy (Feder 2025) — though the RCT record is not uniform, which is why the evidence table below tells the whole story. The 50 mg SL OTF achieves parent-drug Cmax comparable to Spravato 56–84 mg. And at-home sublingual ketamine has a robust real-world safety record across 11,441 patients — at average doses roughly 7× the Project Lucid dose, which makes the observed 0.05% serious-adverse-event rate a conservative upper bound for our exposure, not an extrapolation upward.
Protocol: 6 IV infusions (0.5 mg/kg), 3×/week × 2 weeks. Directly establishes the 3×/week schedule as evidence-based for PTSD.
View on PubMedAmong the largest effect sizes ever reported in psychiatric pharmacotherapy. Project Lucid's digital platform is designed to deliver this combination model at home.
View on PubMed CentralThe 50 mg SL OTF — the same LTS Lohmann platform underlying Project Lucid — was characterized in a Phase 1 PK trial by Dahan et al. (2022). The key finding: the OTF achieves parent-drug S-ketamine Cmax of ~96 ng/mL, comparable to Spravato 56–84 mg intranasal — not half a Spravato 28 mg, as the lower systemic AUC might suggest.
| Parameter | 50 mg SL OTF Project Lucid |
Spravato 28 mg IN | Spravato 56 mg IN | Spravato 84 mg IN |
|---|---|---|---|---|
| Bioavailability | ~29% | ~48% | ~48% | ~48% |
| Systemic S-ket delivered | ~14.5 mg | ~13.4 mg | ~26.9 mg | ~40.3 mg |
| S-ketamine Cmax (ng/mL) | ~96 | 43.8 | 72.5 | 101.0 |
| S-norketamine Cmax (ng/mL) | ~276 | 59.1 | 119.7 | 180.0 |
| Norketamine : Ketamine ratio | ~4.6× | ~1.4× | ~1.7× | ~1.8× |
| Tmax (min) | ~19 | 20–40 | 20–40 | 20–40 |
Source: Dahan et al. 2022 (OTF); J&J / FDA Clinical Pharmacology Review (Spravato). IN = intranasal. Spravato bioavailability includes nasal + GI components.
The SL route’s heavy hepatic first-pass metabolism generates a pharmacologically advantageous metabolite profile. S-norketamine Cmax (276 ng/mL) is 4.6× the parent drug — vs. 1.4–1.8× for Spravato intranasal. The OTF also generates meaningful S-hydroxynorketamine (S-HNK, Cmax ~101 ng/mL), essentially absent in intranasal delivery. Both metabolites show antidepressant and synaptogenic activity in preclinical models — S-HNK without NMDA-receptor antagonism, and now with clean first-in-human Phase 1 safety data (Raja et al., 2024: well tolerated, no dissociation) — though metabolite efficacy has not yet been tested in patients, and recent human PK/PD work attributes part of oral ketamine’s subjective effects to S-norketamine (Otto et al., 2026). The SL route is not a compromise — it is a differentiated pharmacology, and characterizing it is part of the trial’s PK aim.
This metabolite advantage now has transcriptomic confirmation: Wellington et al. (2025, OKTOP cohort) demonstrated that oral ketamine induces a two-phase immune response in PTSD patients — acute IL-6/IL-1β suppression followed by sustained immune reconstitution with an 8.8-fold increase in pathway activity. The modulated pathways (IL-17 z=3.36, interferon α/β z=4.0, cytokine storm z=4.26) are the same targets as Skyrizi (IL-23/IL-17), Cosentyx (IL-17A), Humira (TNFα), and Actemra (IL-6). This provides mechanistic support for the exploratory neuroimmune biomarkers Project Lucid is measuring in the trial.
An honest appraisal of what is known, what is inferred, and what gap Project Lucid fills.
| Scientific Dimension | Evidence Level | Key Sources |
|---|---|---|
| PTSD unmet need | Strong | VA/DoD CPG 2023; PTSD market data |
| Ketamine efficacy in PTSD (3×/week IV) | Strong (RCT) | Feder 2021, Feder 2025 |
| Consistency across IV ketamine RCTs | Mixed — the honest picture | The largest multi-site trial (Abdallah et al. 2022, CAP-ketamine) found no overall benefit over placebo; a 2025 systematic review found 2 of 7 RCTs positive. Effect appears protocol- and population-dependent, and optimal dose is unsettled — the specific questions a randomized dose-ranging trial answers. |
| 50 mg OTF pharmacokinetics | Strong (Phase 1) | Dahan et al. 2022 |
| Therapeutic dose adequacy of 50 mg OTF | Moderate-Strong | Cmax ~96 ng/mL comparable to Spravato 56–84 mg |
| S-HNK / S-norketamine metabolite activity | Moderate (mechanistic; not yet proven in patients) | Zanos 2016; Raja 2024 (HNK Phase 1 — safe, non-dissociative in humans; efficacy untested); Wellington 2025 (OKTOP transcriptomics) |
| 3×/week schedule neuroplasticity rationale | Strong | ASL imaging; Singh et al.; Feder protocols |
| Fear reconsolidation mechanism | Moderate (pilot RCT, biomarker-level) | Duek et al. 2023 |
| At-home SL ketamine safety (N=11,441) | Strong (prospective) | Wolfson et al. 2023; Mindbloom PTSD data |
| Long-term esketamine safety (129 sessions) | Moderate (N=20) | Ayad et al. 2026; SUSTAIN-3 |
| SL esketamine efficacy specifically in PTSD | Absent — gap we fill | N/A — rationale by extrapolation. This is what LUCID-PTSD-2026-001 directly addresses. |
Pivotal RCT establishing 3×/week ketamine as evidence-based for PTSD. 67% vs. 20% response rate; d=1.13; CAPS-5 reduction of 11.9 points vs. 2.4 for midazolam.
View on PubMedOpen-label trial combining 3×/week IV ketamine with WET. d=1.9 — among the largest effect sizes in psychiatric pharmacotherapy, with the open-label caveat that entails. 69% response at Week 12; 61.5% remained responders at 6 months.
View on PMCPhase 1 PK trial of the LTS 50 mg S-ketamine OTF. Establishes ~29% bioavailability, Cmax ~96 ng/mL (comparable to Spravato 56–84 mg), and the 4.6× norketamine metabolite advantage.
View on PMCRandomized pilot (N=27): single ketamine infusion after trauma-memory retrieval, followed by brief exposure therapy, vs. midazolam. Symptoms improved in both groups, but ketamine recipients showed reduced amygdala and hippocampal reactivity to trauma cues through 30-day follow-up — biomarker evidence that ketamine can modify traumatic memories during the reconsolidation window.
View on NatureLargest prospective safety dataset for sublingual ketamine. At average doses 7× the Project Lucid dose: adverse events 3–5%, serious adverse events 0.05%, intense dissociation requiring discontinuation 0.1%. No drug-related fatalities.
View on PMCMost comprehensive long-term esketamine safety data to date: 20 TRD patients, mean 129 intranasal sessions over 2.5 years. No serious adverse events. Side effects mild and transient at all sessions. 85% of patients improved after 129 sessions.
View on PMCMeta-analysis of 20 studies (N>1,000) demonstrating significantly elevated IL-6, IL-1β, and CRP in PTSD — the founding evidence for the neuroinflammatory substrate. Now reinforced a decade later: Yang et al. (2025, Behav Brain Res), across 43 studies, confirm elevated peripheral IL-6 in PTSD (Hedges' g = 0.49).
View on PubMedComprehensive review of NMDA receptor antagonism, downstream BDNF upregulation, and AMPA potentiation. Establishes that the therapeutic mechanism extends well beyond glutamate modulation and supports the rationale for repeated sub-dissociative dosing.
View on PubMedReal-world dataset of 1,247 patients receiving at-home sublingual ketamine. Significant improvement at 1, 2, and 3 months. Extended by Parks et al. (2026, JMIR): N=3,870 at-home patients, adverse events 2.8–3.2%, no serious complications, 84.6% of PTSD patients reaching clinically meaningful improvement. Directly validates Project Lucid’s delivery model at scale.
View on PubMed6-week low-dose oral ketamine trial in 25 PTSD patients — the protein-level companion to the OKTOP transcriptomics. Serum BDNF and VEGF-A decreased with treatment, with a reciprocal BDNF–VEGF-A interaction; protein-level cytokines were unchanged in a cohort where only about half had baseline low-grade inflammation. A candid data point that shapes — rather than settles — the biomarker hypothesis Project Lucid's pre-specified panel tests.
Double-blind, active-controlled single-dose crossover in 33 treatment-resistant PTSD patients. IM ketamine vs. fentanyl (psychoactive control). Ketamine — particularly 1 mg/kg — produced substantial acute PTSD severity reduction (IESR), with some effect persisting at 1 week. Efficacy against an active psychoactive comparator argues against pure placebo or expectancy effects.
RNA transcriptomics in N=23 PTSD patients receiving 6-week oral ketamine. Identified 1,154 differentially expressed genes with an 8.8-fold enhancement in pathway activity from short-term to sustained timepoints. Demonstrated a two-phase immune response: acute pro-inflammatory cytokine suppression (IL-6, IL-1β, CXCL8) followed by sustained immune reconstitution and tissue repair. Key pathways: interferon α/β signalling, IL-17, cytokine storm modulation. The most granular molecular evidence to date that oral ketamine engages the neuroinflammatory substrate in PTSD. Caveat: this is transcript-level (mRNA) evidence — the same cohort's protein-level cytokine panel showed no significant change (Quigley et al., 2026), which is exactly the transcript-to-protein gap Project Lucid's pre-specified biomarker aim is designed to interrogate.
View on PubMedThe same inflammatory substrate that perpetuates PTSD — chronically elevated IL-6, TNF-α, IL-17, and interferon signaling — is central to autoimmune disease. PTSD patients carry 2× the rate of autoimmune conditions (O’Donovan et al., 2015; N=666,269). Oral ketamine modulates these identical pathways, establishing why Project Lucid measures inflammatory biomarkers as an exploratory aim in the PTSD trial.
N=666,269 veterans. Adjusted relative risk of 2.00 for any autoimmune disorder in PTSD vs. no psychiatric diagnosis; 1.51 vs. other psychiatric conditions. First large-scale demonstration that PTSD specifically — not psychiatric illness generally — drives autoimmune risk. Foundational epidemiological basis for measuring inflammatory biomarkers in the PTSD trial.
View on PubMedSwedish population cohort, N=1.2 million. PTSD diagnosis associated with HR=1.46 for any autoimmune disease and HR=2.29 for ≥3 simultaneous autoimmune conditions. Incidence 9.1 vs. 6.0 per 1,000 person-years. Published in JAMA — the highest-impact confirmation of the PTSD-autoimmune comorbidity, and the rationale for measuring inflammatory biomarkers in PTSD trials.
View on PubMedFirst comprehensive meta-analysis of the PTSD-autoimmune association. N=1.98 million across multiple cohorts. Pooled RR=1.291 (95% CI: 1.179–1.412). Confirms the association is robust, consistent across study designs, and not driven by any single cohort or autoimmune subtype. The definitive quantitative synthesis of the PTSD-autoimmune comorbidity — grounding the exploratory biomarker panel.
View on PMCDemonstrated that ketamine directly suppresses Th17 cell differentiation via STAT3/IL-21 pathway inhibition. In an experimental autoimmune encephalomyelitis (EAE) model — the standard animal model for MS — ketamine reduced clinical disease scores from 2.83 to 0.25 (p=0.0025). The most direct mechanistic evidence that ketamine modulates the Th17/Treg axis — supporting the rationale for measuring IL-17 and related biomarkers as exploratory signals in the PTSD trial.
View on PMCThe key transcriptomic evidence. RNA transcriptomics in N=23 PTSD patients on 6-week oral ketamine. Demonstrated modulation of IL-17 signaling (z=3.36), interferon α/β (z=4.0), cytokine storm (z=4.26), and neutrophil degranulation (z=6.0) — the identical pathways targeted by Skyrizi, Cosentyx, Humira, and Actemra. 8.8-fold enhancement in pathway activity from short-term to sustained timepoints. Provides the mechanistic rationale for why Project Lucid measures these inflammatory pathways as exploratory biomarkers in the PTSD trial.
View on PubMedMillennium Cohort Study, N=120,572 active duty. HR=1.58 for composite autoimmune outcome in PTSD vs. non-PTSD. Critically, behavioral factors (smoking, BMI, alcohol) barely attenuated the effect — demonstrating the PTSD-autoimmune link is biologically mediated, not explained by lifestyle confounders. Strongest evidence for a direct inflammatory pathway.
View on PMCThe Wellington transcriptomic data demonstrates that oral ketamine modulates IL-17, interferon, and TNF-α pathways in PTSD patients. The Lee et al. EAE data demonstrates that ketamine directly suppresses Th17 cell differentiation. The O’Donovan, Song, and Mandagere epidemiological data confirms that PTSD and autoimmune disease share a measurable inflammatory substrate. These bodies of evidence are why Project Lucid collects inflammatory biomarkers and disease activity scores as exploratory endpoints in the PTSD trial — not as a go/no-go for a separate program, but as a mechanistic hypothesis worth measuring.
Dallas-based psychiatrist and PTSD specialist who developed Project Lucid directly from clinical ketamine experience. Sponsor-Investigator and IND holder for LUCID-PTSD-2026-001 — a randomized, double-blind, placebo-controlled Phase 1/2a dose-ranging trial of sublingual esketamine film for PTSD.
The clinical premise of Project Lucid sits at the intersection of three bodies of evidence that have not previously been connected: Feder et al.’s RCT-validated 3×/week IV ketamine protocol, Dahan et al.’s Phase 1 PK characterization of the 50mg SL OTF, and Wolfson et al.’s at-home safety dataset of N=11,441. The synthesis is Dr. Idell’s.
Protocol LUCID-PTSD-2026-001 (v4.2) is complete and patent-pending (administration protocol and digital monitoring system), with a ~$6.25M DoD PRMRP Clinical Trial Award application in progress to fund its execution. Dr. Idell is the Sponsor-Investigator.
Dr. Mukesh Kumar, PhD, RAC
CEO & Founder, FDAMap — Washington, DC. 20+ years in FDA regulatory affairs. 150+ clinical trials across 34 countries. Confirmed 505(b)(2) pathway viability for Project Lucid.
Dr. Steven Idell, MD, PhD
Pulmonary & Critical Care Physician. Temple Chair in Pulmonary Fibrosis. 40 years of continuous NIH funding. Founder of Lung Therapeutics (acquired → Rein Therapeutics). Deep translational drug development expertise.
EMMES Corporation
Full-service CRO engaged for the Phase 1/2a dose-ranging trial. Specializes in Phase I–IV trials, biostatistics, pharmacovigilance, and FDA regulatory affairs. AI-enabled trial management.
The Other Side
Jon Nelson and Mark Slater — patient-led organization integrating lived experience into Project Lucid from protocol design forward.
A $3.5B PTSD market with no approved biologic, no novel mechanism approved in 25 years, and a 50% first-line treatment failure rate. Project Lucid is designed to fill that gap with a regulatory pathway confirmed, human PK data in hand, and an integrated exploratory neuroimmune biomarker panel that may generate mechanistic insights for future research.
PTSD patients carry 2× the rate of autoimmune disease (O’Donovan et al., 2015; N=666,269). Wellington et al. (2025) demonstrated that oral ketamine modulates the identical inflammatory pathways as leading autoimmune biologics — IL-17 signaling, interferon α/β, and cytokine storm pathways. Project Lucid’s Phase 1/2a trial uses CAPS-5 dose–response as the primary analysis and carries a pre-specified mechanistic biomarker aim — CRP, IL-6, TNF-α, and BDNF — testing whether baseline inflammatory tone predicts treatment response. Human data on inflammation as a response moderator are promising but mixed — a question the pre-specified aim is designed to answer, not assume.
Primary CAPS-5 dose–response endpoint. 505(b)(2) IND pathway confirmed. Phase 1/2a dose-ranging → Phase 2b → NDA. Positioned alongside Spravato at ~$64K/year reimbursement.
IL-6, TNF-α, IL-17A, IFN-α, CRP, BDNF, and disease activity scores collected as exploratory endpoints. If confirmed, informs future mechanistic research. Not a go/no-go for a separate program.
The Phase 1/2a data is the primary catalyst. A confirmed PTSD dose–response signal drives the Phase 2b RCT and the Series A. A confirmed exploratory neuroimmune signal informs future mechanistic research partnerships.
| Project Lucid | Spravato® (J&J) | IV Ketamine Clinics | Compounded Troches | Autoimmune Biologics | |
|---|---|---|---|---|---|
| PTSD Indication | Phase 1/2 active | Not indicated | Off-label | Off-label, unregulated | Not applicable |
| Neuroimmune Biomarkers | Exploratory endpoints in PTSD trial | Not collected | Not collected | Not collected | Indication-specific only |
| Integrated Biomarker Panel | Yes — exploratory neuroimmune arm | No | No | No | No (psychiatric comorbidity not addressed) |
| Route | Sublingual film (at-home target) | Intranasal (in-clinic REMS) | IV infusion (in-clinic) | Oral (unregulated) | IV infusion / SC injection |
| Digital Monitoring | Wearable + app (patent-pending) | None (clinician only) | None | None | None |
| Inflammatory Biomarkers | IL-6, TNF-α, IL-17A, IFN-α, IL-10, CRP, BDNF, ESR | Not collected | Not collected | Not collected | Indication-specific only |
| Reimbursement Target | ~$64K/yr (PTSD psychiatric therapy) | ~$64K/yr (TRD only) | $5–10K/yr (cash pay) | $1–2K/yr (cash pay) | $64–250K/yr |
| FDA Pathway | 505(b)(2) confirmed | Approved (TRD) | None (off-label) | None | BLA (each drug) |
| Pre-Specified Go/No-Go | 4 domains + tipping-point | N/A (approved) | N/A | N/A | Standard Phase 3 |
| At-Home Scalability | Designed for it — digital REMS path | Blocked by REMS † | Impossible (IV access) | Unregulated — no FDA path | SC self-inject only (no monitoring) |
| † Spravato’s REMS (Risk Evaluation and Mitigation Strategy) mandates in-clinic administration with 2-hour post-dose observation by a healthcare provider for every dose — a structural barrier to at-home scalability that cannot be removed without a new NDA supplement. The FDA rejected MDMA-assisted therapy for PTSD in August 2024 (Lykos Therapeutics, now Resilient Pharmaceuticals; NDA resubmitted August 2026, decision pending) — and every novel-mechanism PTSD candidate still in development is a clinic-administered, monitored-session model. Project Lucid’s sublingual film, combined with a digital monitoring concordance package planned for the Phase 2b program, is designed to be the first esketamine product to demonstrate non-inferiority of remote monitoring vs. in-clinic observation — the regulatory prerequisite for at-home FDA authorization. | |||||
No other clinical program is testing an NMDA antagonist for PTSD with an integrated exploratory neuroimmune biomarker panel. Project Lucid is the only trial designed to measure this inflammatory signal in a PTSD patient population.
Before a single patient is enrolled, the protocol locks in a tipping-point analysis that stress-tests the primary result. Missing data is imputed at progressively worse outcomes — from last-observed value through return-to-baseline and beyond — to answer: how wrong would we need to be for the finding to disappear?
These thresholds are locked in the protocol (Section 7.10.7) before enrollment begins — not chosen after seeing the data. Combined with an O’Brien-Fleming alpha-spending function and a pre-registered SAP, this is the analytical rigor investors and the FDA expect for an IND-enabling dataset.
Whether you're evaluating an investment or exploring a clinical collaboration, we welcome direct conversations.
Seed-stage funding opportunity. Seed capital funds the IND package, IP, and operations while a ~$6.25M DoD PRMRP award (application in progress) is positioned to fund the Phase 1/2a trial itself. Reach out to receive the full investor deck, protocol summary, and financial projections.
Academic medical center partnerships, site collaboration, and key opinion leader engagement. Trauma psychiatrists, psychopharmacologists, and drug delivery researchers are welcome to reach out about the science and study design.
